364750-81-2

Basic information

• Product Name: (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid
• Synonyms: Boc-4-Me-Pro-OH;1,2-Pyrrolidinedicarboxylicacid,4-Methyl-,1-(1,1-diMethylethyl)ester,(2S,4S)-;N-BOC-cis-4-Methyl-L-Proline;(2s,4s)-n-boc-4-methylpyrrolidine-2-carboxylic acid;(2S,4S)-1-(tert-Butoxycarbonyl)-4-methylpyrrolidine-2-carboxylic acid;(2S,4S)-4-Methyl-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;(4S)-1-Boc-4-Methyl-L-proline/(2S,4S)-1-(tert-butoxycarbonyl)-4-Methylpyrrolidine-2-carboxylic acid
• CAS NO: 364750-81-2
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Mol File: 364750-81-2.mol

Chemical Properties

• Boiling Point: 343 °C
• Flash Point: 161 °C
• Appearance: /
• Density: 1.150
• Vapor Pressure: 1.29E-05mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: 2-8°C
• PKA: 4.02±0.40(Predicted)
• CAS DataBase Reference: (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid(364750-81-2)
• EPA Substance Registry System: (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid(364750-81-2)

Safety Data

• Hazardous Substances Data: 364750-81-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid is used as a building block for the synthesis of complex organic molecules. Its unique structure and functional groups allow for versatile chemical reactions, enabling the creation of a wide range of compounds with diverse properties and applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid is used as a precursor in the development of new pharmaceutical compounds. Its specific stereochemistry and functional groups make it a promising candidate for the synthesis of innovative drugs with potential therapeutic effects.
Used in Drug Synthesis:
(2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid is utilized as an intermediate in the synthesis of various drug molecules. Its Boc protective group can be selectively removed under mild conditions, facilitating the introduction of other functional groups or the formation of specific drug structures.
Used in Chiral Synthesis:
Due to its specific (2S,4S) configuration, (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid is employed in chiral synthesis, where the stereochemistry of the compound is crucial for its biological activity and selectivity. It can be used to prepare enantiomerically pure compounds with desired pharmacological properties.
Used in Catalyst Design:
The unique structure of (2S,4S)-N-Boc-4-methylpyrrolidine-2-carboxylic acid makes it a potential candidate for the design of chiral catalysts. These catalysts can be used in asymmetric synthesis, enabling the selective formation of enantiomerically pure products with high yields and selectivity.

InChI:InChI=1/C11H19NO4/c1-7-5-8(9(13)14)12(6-7)10(15)16-11(2,3)4/h7-8H,5-6H2,1-4H3,(H,13,14)/t7-,8-/m0/s1

Upstream product

• 61-90-5 L-leucine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 540501-56-2 (2S,4S)-tert-butyl 2-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate 
• 138512-73-9 N-Boc-4-methylproline methyl ester 
• 84348-38-9 (S)-1-(tert-butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid 
• 196394-48-6 (2S,4S)-1-tert-butyl 2-methyl 4-methyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 1262320-71-7 tert-butylamine (S)-1-(tert-butoxycarbonyl)-4-(methylene)pyrrolidine-2-carboxylic acid 

Downstream Products

• 901139-29-5 N-tert-butyloxycarbonyl-(2S,4S)-4-methylprolyl-glycine benzyl ester 
• 1233365-43-9 C₁₇H₂₄N₄O₅ 
• 1250939-42-4 (2-(2-(4-bromophenyl)-2-oxoethyl)) 1-(tert-butyl) (2S,4S)-4-methylpyrrolidine-1,2-dicarboxylate 
• 1335208-95-1 (2S,4S)-tert-butyl 2-((2,4-dibromophenyl)carbamoyl)-4-methylpyrrolidine-1-carboxylate 
• 1250939-45-7 C₁₉H₂₄BrN₃O₂ 
• 1377049-02-9 methyl {1-[2-{9-[2-(1-{[(methoxycarbonyl)amino](phenyl)acetyl}-4-methylpyrrolidin-2-yl)-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl}-4-(methoxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 1477816-43-5 {(S)-2-methyl-1-[(2S,4S)-4-methyl-2-(7-{4-[(4-(piperidin-4-yl)piperazine-1-carbonyl)amino]-2-trifluoromethoxyphenyl}-3H-naphtho[1,2-d]imidazol-2-yl)pyrrolidine-1-carbonyl]propyl}carbamic acid methyl ester 
• 1613055-91-6 C₃₁H₃₄F₃N₃O₅S 
• 1335315-65-5 ((S)-1-{(2S,4S)-2-[5-(4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1335316-23-8 (2S,4S)-2-[4-(4'-bromo-biphenyl-4-yl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula (I) or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R1, R1 ', R2, R2', R3, R3', R5, R5', R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Total synthesis and stereochemical reassignment of bisebromoamide

A revised configurational assignment for the thiazoline moiety of the marine peptide bisebromoamide is proposed and validated by total synthesis.

Collagen mimics

Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n, where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix is increased due solely to steric effects relative to prior known collagen-related triple helices. Methods are also disclosed for making the novel collagen mimics.

Reciprocity of steric and stereoelectronic effects in the collagen triple helix

In previous work, we demonstrated that 4-fluoroproline residues can contribute greatly to the conformational stability of the collagen triple helix, and that this stability arises from stereoelectronic effects that fix the pucker of the pyrrolidine ring and thereby preorganize the backbone properly for triple-helix formation. Here, we take a reciprocal approach, demonstrating that the steric effect of a 4-methyl group confers stability similar to that from a 4-fluoro group in the opposite configuration. Such fundamental interplay between steric and stereoelectronic effects is heretofore unknown in proteinsnatural or syntheticand provides a new means to modulate conformational stability. Copyright